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Context: Obesity acts as a cardiovascular risk factor by mechanisms
that are not fully understood. Osteopontin (OPN) is a proinflamma-
tory mediator involved in tissue remodeling that plays a role in ath-
erosclerosis and diabetes.
Objective: The aim of the present study was to compare the circu-
lating concentrations of OPN and its mRNA expression in omental
adipose tissue of lean, overweight, and obese individuals and to an-
alyze the effect of weight loss.
Subjects and Methods: Plasma concentrations of OPN were mea-
sured in 77 volunteers. OPN mRNA expression in omental adipose
tissue obtained from 12 women was quantified by real-time PCR. In
addition, the concentrations of OPN in 12 obese men were measured
before and after weight loss following a dietetic program.
Setting: The study was conducted at a University Hospital.
Results: Obese and overweight patients exhibited significantly in-
creased circulating OPN concentrations as compared with lean sub-
jects (obese 72.6  28.5, overweight 68.2  20.8, lean 42.7  27.9
ng/ml; P  0.001). A significant positive correlation was found be-
tween OPN levels and body fat (r  0.45; P  0.0001). Obese indi-
viduals showed significantly increased (P  0.05) mRNA expression
of OPN in omental adipose tissue as compared with lean volunteers,
which was further increased in obese diabetic patients. Diet-induced
weight loss significantly decreased OPN concentrations from 64.7 
22.1 to 36.6  20.1 ng/ml (P  0.006).
Conclusions: These findings represent the first observation that
plasma OPN and mRNA expression of OPN in omental adipose tissue
are increased in overweight/obese patients with the latter being fur-
ther elevated in obesity-associated diabetes. Moreover, weight loss
reduces OPN concentrations, which may contribute to the beneficial
effects accompanying weight reduction. Measurement of OPN might
be useful for evaluating the outcomes of various clinical interventions
for obesity-related cardiovascular diseases. (J Clin Endocrinol
Metab 92: 3719–3727, 2007)
OBESITY IS ASSOCIATED with alterations in myocar-dial and vascular structure as well as physiology,
which are accompanied by an adverse risk factor profile
leading to the development of cardiovascular disease (1–3).
This circumstance favors the clustering of metabolic and
cardiovascular alterations leading to an increase in morbidity
and mortality in relation to excess adiposity (4–6).
Osteopontin (OPN), also known as early T lymphocyte
activation (Eta-1), secreted phosphoprotein-1 (SPP1), and
bone sialoprotein-1 among others, is a phosphoprotein ex-
pressed by a wide variety of cell types, such as osteoclasts,
lymphocytes, endothelial cells, macrophages, epithelial cells,
hepatocytes, and vascular smooth muscle cells. OPN signals
through integrin receptors and isoforms of CD44 (also
known as extracellular matrix receptor type III), whereby it
is involved in several pathophysiological processes includ-
ing bone remodeling, immunity, inflammation, neoplastic
transformation, progression of metastases, promotion of cell
survival, and wound healing (7, 8).
In addition, OPN has been shown to exert an impact on
the cardiovascular sphere, playing a role in atherosclerosis
(9 –12), left ventricular hypertrophy (13), and cardiac fi-
brosis (14), processes frequently associated with obesity
(15–17). Furthermore, OPN mRNA expression is up-reg-
ulated in the heart of infarcted obese mice (18). OPN has
also been involved in diabetic vascular disease (9, 19) as
well as in the development of nonalcoholic steatohepatitis
(20). Expression of OPN in adipose-derived stem cells, but
not in adipocytes, has been previously reported (21). How-
ever, to date, neither circulating concentrations of OPN in
human obesity nor OPN expression in adipose tissue has
been investigated.
The present study explores the actual plasma levels of
OPN as well as the mRNA expression of OPN in omental
adipose tissue in human obesity. We hypothesized that
plasma OPN concentrations will be increased in accordance
with the degree of adiposity. To validate this assumption
further, we assessed the effect of weight loss on plasma OPN
levels.
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Patients and Methods
Patient selection and study design
To analyze the effect of obesity on OPN concentrations, 77 Caucasian
subjects (26 lean, 14 overweight, and 37 obese) were recruited from
healthy volunteers and patients attending the Endocrinology and Sur-
gery Departments at the University Clinic of Navarra. Subjects were
classified according to body mass index (BMI) (lean, 25; overweight,
25–29.9; and obese, 30 kg/m2). Patients underwent a clinical assess-
ment including medical history, physical examination, body composi-
tion analysis, and comorbidity evaluation as well as nutritional inter-
views performed by a multidisciplinary consultation team. All subjects
were nonsmokers. Patients with signs of infection were excluded. Obese
patients were not receiving statins or antidiabetic medication. Normo-
glycemia (NG), impaired glucose tolerance (IGT), and type 2 diabetes
mellitus (T2DM) are defined following the criteria of the Expert Com-
mittee on the Diagnosis and Classification of Diabetes Mellitus (22)
based on both fasting plasma glucose concentrations and plasma glucose
2 h after an oral glucose tolerance test (OGTT).
In addition, mRNA expression of OPN in omental adipose tissue was
assessed in a separate group of female obese patients after a Roux-en-Y
gastric bypass (n 8) and in a group of lean patients undergoing Nissen
fundoplication (n  4) for the treatment of hiatus hernia.
Furthermore, the effect of weight loss on plasma OPN concentrations
in a different group of 12 obese male patients was analyzed. Weight loss
was achieved by prescription of a diet providing a daily energy deficit
of 500-1000 kcal/d as calculated from the determination of the resting
energy expenditure through indirect calorimetry (Vmax29; SensorMed-
ics Corp., Yorba Linda, CA) and multiplication by the physical activity
level factor to obtain the individual’s total energy expenditure. This
hypocaloric regime allows a safe and steady weight loss of 0.5–1.0
kg/wk when strictly followed and supplied 30, 54, and 16% of energy
requirements in the form of fat, carbohydrates, and protein, respectively.
The experimental design was approved, from an ethical and scientific
standpoint, by the Hospital’s Ethical Committee responsible for re-
search, and volunteers gave their informed consent to participate in all
the studies.
Anthropometric measurements
Body weight was measured with a digital scale to the nearest 0.1 kg,
and height was measured to the nearest 0.1 cm with a Holtain stadi-
ometer (Holtain Ltd., Crymych, UK). BMI was calculated as weight in
kilograms divided by the square of height in meters. Body fat was
estimated by air-displacement plethysmography (Bod-Pod; Life Mea-
surements, Concord, CA). Data for estimation of body fat by this ple-
thysmographic method has been reported to agree closely with the
traditional gold standard hydrodensitometry (underwater weighing).
Furthermore, the Bod-Pod has been shown to predict fat mass and
fat-free mass more accurately than dual-energy x-ray absorptiometry
and bioelectrical impedance (23–25). Blood pressure was measured after
a 5-min rest in the semi-sitting position with a sphygmomanometer.
Blood pressure was determined at least three times at the right upper
arm, and the mean was used in the analyses.
Analytical procedures
Blood samples were collected after an overnight fast in the morning
to avoid potential confounding influences due to hormonal rhythmicity.
Plasma glucose was analyzed by an automated analyzer (Roche/Hitachi
Modular P800) as previously described (26, 27). Insulin was measured
by means of an enzyme-amplified chemiluminescence assay (IMMU-
LITE; Diagnostic Products Corp., Los Angeles, CA). An indirect measure
of insulin sensitivity was calculated from the fasting plasma glucose and
insulin concentrations by using the quantitative insulin sensitivity check
index (QUICKI) (28, 29). Total cholesterol and triglyceride concentra-
tions were determined by enzymatic spectrophotometric methods
(Roche, Basel, Switzerland). High-density lipoprotein (HDL)-cholesterol
was quantified by a colorimetric method in a Beckman Synchron CX
analyzer (Beckman Instruments, Ltd., Bucks, UK). Low-density lipopro-
tein (LDL)-cholesterol was calculated by the Friedewald formula.
Uric acid, alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST), alkaline phosphatase, -glutamyltransferase (-GT), and cre-
atinine were measured by enzymatic tests (Roche) in an automated
analyzer (Roche/Hitachi Modular P800). Fibrinogen concentrations
were determined according to the method of Clauss using a commer-
cially available kit (Hemoliance; Instrumentation Laboratory, Barcelona,
Spain). Measurement of von Willebrand factor (vWF) antigen was per-
formed by a micro-latex immunoassay (Diagnostica Stago, Inc., Parsip-
pany, NJ). A standard curve was prepared with a universal reference
(NISBC 91/666), and the results were expressed as percentage of the
standard. Intra- and interassay coefficients of variation were 4.0 and
8.0%, respectively. High-sensitivity C-reactive protein (CRP) was mea-
sured using the Tina-quant CRP (Latex) ultrasensitive assay (Roche).
Leptin was quantified by a double-antibody RIA method (Linco Re-
search, Inc., St. Charles, MO); intra- and interassay coefficients of vari-
ation were 5.0 and 4.5%, respectively. Adiponectin was measured by
ELISA (BioVendor, Brno, Czech Republic); intra- and interassay coef-
ficients of variation were 6.7 and 7.8%, respectively. TNF- was quan-
tified by a high-sensitivity ELISA (R&D Systems, Abingdon, UK); intra-
and interassay coefficients of variation were 6.7 and 13.4%, respectively.
OPN was determined by ELISA (R&D Systems) with intra- and inter-
assay coefficients of variation being 3.2 and 5.9%, respectively.
Bone mineral density (BMD)
In a subset of obese patients (n  20), BMD was measured by dual
x-ray absorptiometry using a Hologic QDR4500-W densitometer (Ho-
logic, Inc., Bedford, MA). The area of BMD in grams per square centi-
meter was measured at the lumbar spine (L2–L4) as well as at the femoral
neck, Ward’s triangle, trochanter, and total hip. The manufacturer’s
software calculated bone mineral content and areal BMD for each ver-
tebra. The average BMD of L2–L4 were determined by averaging the
values for L2, L3, and L4. The time required for the procedure was
approximately 5 min, and the radiation exposure was negligible. Os-
teoporosis and osteopenia were defined, according to the World Health
Organization criteria at any measured site relative to age- and sex-
related reference values (30).
OPN and CD68 immunohistochemistry in adipose tissue
Immunohistochemistry was carried out using the osteopontin (hu-
man) immunohistochemistry staining kit (Bachem AG, Bubendorf, Swit-
zerland) following the manufacturer’s instructions or following a pre-
viously described protocol for CD68 (31). Briefly, sections (6 m) of
formalin-fixed, paraffin-embedded omental adipose tissue from an
obese subject were dewaxed in xylene and rehydrated in decreasing
concentrations of ethanol and tap water. Subsequently, sections were
immersed in 10 mmol/liter citrate buffer (pH 6.0) and heated using a
microwave oven at 800 W for 15 min to enhance antigen retrieval. After
cooling, sections were treated with 3% H2O2 in water for 20 min for
quenching of endogenous peroxidase activity. Then, slides were blocked
during 15 min with 100 l normal goat serum blocking solution (OPN)
or murine serum (Sigma Chemical Co., St. Louis, MO) (CD68) to prevent
nonspecific adsorption. Sections were incubated overnight at 4 C with
100 l rabbit antihuman OPN antibody raised against a peptide corre-
sponding to residues 170–187 of human OPN (Bachem) or monoclonal
mouse antihuman CD68 antibody (M0876; DakoCytomation, Glostrup,
Denmark) at a concentration of 10 g/ml. Sections were washed three
times (2 min each) with Tris-buffered saline Tween 20 (TBST) and then
incubated for 45 min at RT with 100 l biotinylated goat antirabbit
secondary antibody for OPN (Bachem) or sheep antimouse polyclonal
IgG for CD68 (NXA931; Amersham, Buckinghamshire, UK) diluted
1:100 in TBST. After washing in TBST, sections were incubated with 100
l of streptavidin-horseradish peroxidase conjugate for 30 min. Sections
were washed three times with TBST and incubated 3 min with 100 l
substrate-chromogen mixture (3,3-diaminobenzidine/H2O2 solution)
and counterstained with 100 l Mayer’s hematoxylin for 2 min. Sections
were washed in tap water, immersed in PBS (pH 7.4), rinsed in distilled
water, coverslipped, and observed under a Zeiss Axiovert 40 CFL optic
microscope (Zeiss, Go¨ttingen, Germany). Negative control slides with-
out primary antibody were included to assess nonspecific staining.
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OPN and CD68 mRNA expression quantification by real-
time PCR
Omental adipose tissue was obtained from 12 female patients un-
dergoing either Roux-en-Y gastric bypass (n  8) or Nissen fundopli-
cation (n  4). The samples were immediately frozen in liquid nitrogen
and stored at 80 C. RNA isolation was performed as previously de-
scribed (32). Transcript levels for OPN (SPP1) and CD68 genes were
quantified by real-time PCR (7300 Real-Time PCR System; Applied
Biosystems, Foster City, CA). Primers and probes (Sigma) were designed
using the software Primer Express 1.0 (Applied Biosystems). Primers
used to amplify the cDNA of SPP1 (GenBank NM_001040060) were
5-ACAGCCACAAGCAGTCCAGATTA-3 and 5-TCCTGACTAT-
CAATCACATCGGAAT-3, and the probe was 5-FAM-AGCG-
GAAAGCCAATGATGAGAGCAATG-TAMRA-3 and for CD68 (Gen-
Bank NM_001251) were 5-CACGCAGCACAGTGGACATT-3 and 5-
CGAGTTGCTGCAACTGAAGCT-3, and the probe was 5-FAM-
TCGGCTCAGAATGCATCCCTTCGA-TAMRA-3. The cDNA was
amplified at the following conditions: 95 C for 10 min, followed by 45
cycles of 15 sec at 95 C and 1 min at 59 C, using the TaqMan Universal
PCR Master Mix (Applied Biosystems). The primer and probe concen-
trations for gene amplification were 300 nmol/liter and 200 nmol/liter,
respectively. All results were normalized to the levels of 18S rRNA
(Applied Biosystems), and relative quantification was calculated using
theCt formula (33). Relative mRNA expression was expressed as fold
expression over the calibrator sample (average of gene expression cor-
responding to the lean group). All samples were run in triplicate and the
average values were calculated.
Statistical analysis
Data are presented as mean  sd. Differences between groups were
analyzed by ANOVA followed by Fisher’s least significant difference
tests for computing the differences between lean, overweight, and obese
groups, by Kruskal-Wallis followed by U Mann-Whitney’s tests for
analyzing the differences between groups in the expression study, and
by two-tailed paired t tests for comparison of the weight loss effect. CRP
and leptin concentrations were logarithmically transformed in the first
study, because of their nonnormal distribution. The distribution of other
variables was adequate for the application of parametric tests. Corre-
lations between two variables were computed by Pearson’s correlation
coefficients (r) or Spearman’s rank correlation coefficients () as appro-
priate. The calculations were performed using the SPSS version 13.0.1
(SPSS, Chicago, IL). A P value lower than 0.05 was considered statisti-
cally significant.
Results
Patient characteristics and metabolic profile
No statistically significant differences for gender distribu-
tion were found between the groups (Table 1). As expected,
body fat was significantly higher (P  0.0001) in the over-
weight and obese subjects, who also showed lower insulin
sensitivity than lean individuals as evidenced by the lower
QUICKI (P  0.0001). However, increased concentrations of
glucose (P  0.003) and insulin (P  0.001) were observed
only in the obese group. Circulating concentrations of total
cholesterol (P  0.0001) and LDL-cholesterol (P  0.0001)
were significantly increased in the overweight and obese
individuals, whereas HDL-cholesterol was reduced (P 
0.0001). The inflammatory markers CRP and TNF- were
significantly increased (P  0.0001) in both overweight and
obese patients. Fibrinogen, homocysteine, and vWF concen-
trations were higher in obese individuals (P  0.001), to-
gether with an impaired hepatic function as evidenced by
increased levels of transaminases, alkaline phosphatase, and
TABLE 1. Characteristics of lean, overweight, and obese subjects
Lean Overweight Obese P
n 26 14 37
Sex (male/female) 11/15 7/7 19/18 0.769
Age (yr) 32.8  10.8 37.1  14.1 40.8  10.8a 0.028
BMI (kg/m2) 20.4  2.3 26.8  1.6a 41.0  5.4a,b 0.0001
Body fat (%) 19.3  5.8 35.4  6.6a 46.3  7.1a,b 0.0001
SBP (mm Hg) 106  13 106  11 129  16a,b 0.0001
DBP (mm Hg) 68  9 66  6 81  11a,b 0.0001
Glucose (mmol/liter) 4.6  0.6 5.2  0.6 5.8  1.8a 0.003
Insulin (U/ml) 5.8  3.1 10.3  4.0 19.2  11.5a,b 0.0001
QUICKI 0.385  0.038 0.340  0.021a 0.3140.029a,b 0.0001
Triglycerides (mmol/liter) 0.7  0.3 1.3  0.9 1.9  2.2a 0.019
Cholesterol (mmol/liter) 4.2  0.9 5.4  1.2a 5.3  1.3a 0.001
LDL-cholesterol (mmol/liter) 2.3  0.7 3.2  1.0a 3.3  1.0a 0.001
HDL-cholesterol (mmol/liter) 1.6  0.3 1.4  0.4a 1.1  0.2a,b 0.0001
Uric acid (mg/dl) 4.1  0.8 4.9  1.2 6.6  1.4a,b 0.0001
Fibrinogen (mg/dl) 179  44 335  77a 328  72a 0.0001
vWF (%) 81  29 96  31 124  39a 0.001
Homocysteine (mol/liter) 6.2  1.4 8.0  1.03 8.9  3.4a 0.001
CRP (mg/liter) 0.7 (0.4–1.0) 3.5 (0.4–5.9)a 7.4 (2.4–11.8)a,b 0.0001
TNF- (pg/ml) 1.51  0.42 2.12  0.92a 2.16  1.10a 0.021
ALT (IU/liter) 8  6 19  24a 31  19a,b 0.0001
AST (IU/liter) 11  6 16  10 18  10a 0.021
Alkaline phosphatase (IU/liter) 76  25 82  25 96  31a 0.014
-GT (IU/liter) 11  3 15  10 31  23a,b 0.0001
Creatinine (mg/dl) 0.81  0.09 0.86  0.16 0.84  0.13 0.396
Adiponectin (g/ml) 13.8  7.0 9.1  4.8a 8.9  4.0a 0.002
Leptin (ng/ml) 6.5(4.3–9.6) 22.0 (9.4–29.7)a 47.3 (31.2–73.2)a,b 0.0001
Data are presented as mean  SD or median (interquartile range). Differences between groups were analyzed by ANOVA followed by least
significant difference tests. Differences in gender distribution were analyzed by 2 analysis. CRP and leptin concentrations were logarithmically
transformed for statistical analysis. To convert glucose to mg/dl, divide by 0.05551; to convert values for triglycerides to mg/dl, divide by 0.01129;
to convert values for cholesterol to mg/dl, divide by 0.02586. DBP, Diastolic blood pressure; SBP, systolic blood pressure.
a P  0.05 vs. lean.
b P  0.05 vs. overweight.
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-GT. As expected, the increased body fat values of over-
weight and obese patients were accompanied by hypoadi-
ponectinemia (P  0.002) and hyperleptinemia (P  0.0001).
Obesity and OPN concentrations
Circulating concentrations of OPN were significantly in-
creased in obese and overweight patients (obese 72.6 28.5,
overweight 68.2  20.8, lean 42.7  27.9 ng/ml; P  0.001)
compared with lean subjects (Fig. 1). No differences between
overweight and obese patients were observed (P  0.611),
probably due to the high body fat percentage displayed
despite exhibiting a BMI within the range of 25–30 kg/m2 by
the overweight subjects (Fig. 2). OPN levels were slightly
higher in obese individuals with IGT or T2DM (n 18; 76.2
31.6 ng/ml) compared with obese NG patients (n 19; 69.1
25.7 ng/ml), but the differences fell out of statistical signif-
icance (P  0.458). No significant differences between male
(60.2  30.8 ng/ml) and female patients (63.1  29.7 ng/ml)
were observed. A highly significant positive correlation was
found between OPN and body fat percentage (r  0.45; P 
0.0001; Fig. 2). OPN levels were significantly correlated with
several variables as shown in Table 2. However, after ad-
justing for body fat, only the associations of OPN with in-
sulin, QUICKI, uric acid, vWF, CRP, alkaline phosphatase,
and hepatic enzymes (ALT, AST, and -GT) remained sta-
tistically significant. The significantly elevated levels of he-
patic enzymes exhibited by the obese patients suggest that
these subjects may suffer from fatty liver or some other liver
dysfunction influencing OPN concentrations. However,
OPN levels were still associated with body fat percentage
after adjusting for ALT (r  0.34; P  0.003). To analyze the
relation or influence of bone mass with circulating OPN
concentrations, bone densitometry was performed in a sub-
set of 20 obese patients (five male and 15 female); none of
them exhibited osteoporosis. No significant differences (P
0.993) in OPN levels between patients with osteopenia (n 
7; lumbar spine BMD, 0.90  0.05 g/cm2; OPN, 76.3  38.5
ng/ml) and normal subjects (n 13; BMD, 1.13 0.10 g/cm2;
OPN, 76.1  28.1 ng/ml) were observed. OPN concentra-
tions and lumbar spine BMD were not significantly related
(r  0.27; P  0.245).
Detection of OPN in adipose tissue and OPN expression
in obesity
The presence of OPN protein in sections of omental adi-
pose tissue was evaluated by immunohistological analysis
(Fig. 3). Both adipocytes and cells of the stroma-vascular
fraction were immunopositive for OPN (Fig. 3, B and E). As
expected, CD68 staining in adipose tissue was localized only
to macrophages (Fig. 3, C and F). OPN labeling was stronger
in CD68-positive cells, but a marked staining was also ob-
served in fully mature adipocytes. Adipose tissue mRNA
expression of OPN and its relation to the adiposity excess
characteristic of obesity were also analyzed. To gain insight
into this condition, mRNA expression of OPN in omental
adipose tissue was measured in two groups of obese women
classified according to the absence or presence of T2DM and
compared with that of weight-stable lean women. Obese
women with T2DM showed higher glucose concentrations in
the fasting state (P  0.05) and 2 h after an OGTT (P  0.05)
than lean and obese NG individuals. Moreover, they showed
a significant reduction (P  0.05) in adiponectin concentra-
tions in comparison with obese NG women (Table 3).
The mRNA expression of OPN was significantly increased
in omental adipose tissue of obese NG women compared
with lean individuals (2.44  0.88 vs. 1.00  0.52 arbitrary
units, P 0.05; Ct, 5.04 0.60 and 6.37 0.71, respectively;
Fig. 4A) and further increased in obese T2DM women (8.00
4.74, P  0.05 vs. both lean and obese NG; Ct, 3.44  0.88).
CD68 mRNA expression in adipose tissue showed a similar
tendency to that exhibited by OPN expression (obese T2DM
3.06  2.20, obese NG 1.71  0.72, lean 1.00  0.44 arbitrary
units; Ct 4.96  1.13, 5.59  0.63, and 6.37  0.82, respec-
tively; Fig. 4B), but the differences fell out of statistical sig-
nificance (P  0.091). OPN and CD68 mRNA were not sig-
nificantly related (r 0.33; P 0.351). Expression of OPN in
omental adipose tissue was significantly correlated with all
variables analyzed except for age and plasma adiponectin
concentrations (Table 4).
FIG. 1. Comparison of plasma OPN concentrations in the lean, over-
weight, and obese groups. Values are means  SD. Statistical differ-
ences were assessed by one-way ANOVA.
FIG. 2. Scatter diagram showing the highly significant positive cor-
relation found between body fat percentage and circulating concen-
trations of OPN. Pearson’s correlation coefficient and P value are
indicated. Circles represent males, and squares stand for females.
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OPN concentrations after diet-induced weight loss
After an average period of 14 wk following the hypocaloric
regimen, patients lost an average of 8.5 kg (P  0.002), and
their waist circumference decreased a mean of 12.6 cm (P 
0.0001) (Table 5). Significant decreases in BMI, body fat, and
waist-to-hip ratio as well as a significant improvement in
systolic (P 0.001) and diastolic (P 0.004) blood pressures
were also observed. Glucose and insulin concentrations were
within the normal ranges at baseline as well as after weight
loss. Leptin concentrations, as expected after the reduction in
body fat, were significantly reduced (P  0.001). Diet-
induced weight loss produced a statistically significant re-
duction in circulating OPN concentrations (Fig. 5), which
decreased from 64.7 22.1 to 36.6 20.1 ng/ml (P 0.006).
Discussion
The main findings of the present study are 1) that plasma
OPN concentrations are increased in overweight and obese
subjects, 2) that circulating concentrations of OPN correlate
with body fat, 3) that OPN mRNA and protein are expressed
in omental adipose tissue, 4) that the expression in this fat
depot is increased in obesity and further elevated in obesity-
associated T2DM, and 5) that modest diet-induced weight
loss is accompanied by a significant decline in plasma OPN
levels.
This is, to our knowledge, the first study describing in-
creased plasma OPN levels in human obesity. Obese patients
exhibited a 2-fold increase in plasma OPN concentrations
compared with lean individuals. The significant positive cor-
relation found in the present study between OPN and body
fat seems to indicate that OPN levels are related to the ad-
ipose tissue amount. It is noteworthy that our data are the
first to report that OPN is actually expressed by adipose
FIG. 3. Immunostaining of OPN and CD68 in human omental adi-
pose tissue. Immunoreactivity for CD68 was localized to macrophages
(C and F). Positivity (brown staining) was observed for OPN (B and
E) in both fully mature adipocytes and cells of the stroma-vascular
fraction, being stronger for CD68-positive cells (arrow). No immuno-
reactivity was found without any primary antibody (negative control,
A and D). Magnification, 100 (A–C) (scale bar, 80 m) and 400
(D–F) (scale bar, 20 m).
TABLE 2. Univariate analysis of the correlation between OPN and other variables, unadjusted and after adjusting for body fat
Variable
Plasma OPN
Unadjusted correlation Adjusted correlation
r P value r P value
Sex 0.05 0.671 0.08 0.490
Age 0.18 0.119 0.09 0.437
BMI 0.42 0.0001 0.08 0.477
Body fat 0.45 0.0001
SBP 0.22 0.070 0.00 0.986
DBP 0.19 0.108 0.01 0.952
Glucose 0.30 0.009 0.18 0.117
Insulin 0.46 0.0001 0.29 0.010
QUICKI 0.54 0.0001 0.36 0.001
Triglycerides 0.29 0.011 0.22 0.054
Cholesterol 0.34 0.003 0.19 0.111
LDL-cholesterol 0.24 0.035 0.03 0.786
HDL-cholesterol 0.18 0.114 0.01 0.988
Uric acid 0.42 0.001 0.25 0.033
Fibrinogen 0.48 0.0001 0.24 0.052
vWF 0.46 0.001 0.29 0.024
Homocysteine 0.27 0.031 0.11 0.376
CRP 0.52 0.0001 0.30 0.013
TNF- 0.22 0.060 0.06 0.627
ALT 0.43 0.001 0.31 0.006
AST 0.40 0.001 0.34 0.003
Alkaline phosphatase 0.42 0.001 0.33 0.004
-GT 0.43 0.0001 0.31 0.006
Creatinine 0.13 0.262 0.21 0.079
Adiponectin 0.18 0.118 0.10 0.377
Leptin 0.38 0.001 0.09 0.451
Values are Pearson’s correlation coefficients and associated P values. CRP and leptin concentrations were logarithmically transformed for
statistical analysis. DBP, Diastolic blood pressure; SBP, systolic blood pressure.
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tissue. However, OPN is derived from many cellular types,
and the partial contribution of any other organ to circulating
OPN remains unknown (34). Expression of OPN has been
observed, among others, in epithelial cells, macrophages,
and atherosclerotic plaques (8). It has also been reported that
OPN is expressed in adipose-derived stem cells (21). In the
present study, we have demonstrated for the first time the
presence of OPN by immunohistochemistry in human omen-
tal adipose tissue. OPN labeling was stronger in CD68-pos-
itive macrophages as might be expected, but a marked stain-
ing in fully mature adipocytes was evident. Furthermore, we
have analyzed the mRNA expression of OPN, providing
clear evidence that it is highly expressed in omental adipose
tissue and significantly increased in obese patients compared
with lean individuals. It is possible that part of the detected
OPNmRNA is derived from infiltrated macrophages present
in adipose tissue, which are further recruited by OPN itself
in a vicious cycle (8, 35), but the immunohistochemical anal-
ysis shows that OPN is also expressed by adipocytes. There-
fore, OPN secretion by omental adipose tissue may contrib-
ute to the increased circulating levels of OPN observed in
obesity. Because OPN is expressed in both adipocytes and
cells of the stroma-vascular fraction, the quantitative contri-
bution of each cell type remains to be fully elucidated.
The expression of OPN is increased in the liver (20) and in
the infarcted heart (18) of obese mice, which has been related
to fibrosis and recruitment of inflammatory cells, respec-
tively. Moreover, a direct stimulatory effect of leptin on the
expression of OPN has been described to take place in mouse
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FIG. 4. Expression of OPN and CD68 in omental adipose tissue from
lean and obese women. PCR amplification of reverse-transcribed
mRNA was performed on total RNA isolated from individual samples.
Bars represent the mean  SD of the ratio between OPN or CD68 to
18S rRNA from four lean normoglycemic, four obese normoglycemic,
and four obese women with T2DM. The expression of OPN and CD68
in lean subjects was assumed to be 1. Differences between groups were
analyzed by Kruskal-Wallis followed by Mann-WhitneyU tests. *,P
0.05 vs. lean NG; †, P  0.05 vs. obese NG.
TABLE 4. Univariate analysis of correlation between OPN
mRNA in omental adipose tissue and other variables
Variable
OPN mRNA
 P value
Age 0.29 0.359
BMI 0.86 0.001
Body fat 0.71 0.009
Glucose 0.69 0.014
2-h OGTT glucose 0.74 0.006
Insulin 0.67 0.017
QUICKI 0.83 0.001
CRP 0.85 0.001
ALT 0.75 0.005
Adiponectin 0.40 0.223
Leptin 0.70 0.011
Values are Spearman’s correlation coefficients () and associated P
values.
TABLE 3. Characteristics of lean and obese women included in the adipose tissue expression study
Lean NG Obese NG Obese T2DM
n 4 4 4
Age (yr) 35.8  8.8 38.8  9.4 40.5  6.7
BMI (kg/m2) 20.7  2.6 48.1  5.2a 55.0  11.0a
Body fat (%) 26.3  6.2 56.3  2.9a 55.0  4.0a
Glucose (mmol/liter) 4.9  0.5 5.1  0.6 7.9  1.2a,b
2-h OGTT glucose (mmol/liter) 6.1  1.4 6.6  0.6 15.1  6.1a,b
Insulin (U/ml) 7.5  4.1 20.8  10.0a 26.3  13.3a
QUICKI 0.366  0.042 0.309  0.017a 0.285  0.023a
CRP (mg/liter) 2.0  1.2 6.3  2.1a 9.3  3.3a
ALT (IU/liter) 9  2 33  21a 40  21a
Adiponectin (g/ml) 11.6  6.1 8.8  1.9 5.1  1.2b
Leptin (ng/ml) 9.1  4.3 57.2  20.0a 73.6  49.4a
Data are presented as mean SD. Differences between groups were analyzed by Kruskal-Wallis followed by Mann-WhitneyU tests. To convert
glucose to mg/dl, divide by 0.05551.
a P  0.05 vs. lean NG.
b P  0.05 vs. obese NG.
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hepatocytes (20). This finding is in agreement with our data
of high levels of OPN in the setting of hyperleptinemia.
However, OPN concentrations were not significantly asso-
ciated with leptin after adjusting for body fat.
The present study shows that increased body fat is ac-
companied by high concentrations of OPN in addition to
high levels of CRP, TNF-, and fibrinogen, thus reinforcing
the observation that excess adiposity may contribute to the
obesity-associated low-grade chronic inflammation with
OPN emerging as an additional element of this condition. In
this sense, a close association between OPN and CRP after
adjusting for adiposity was found. The proinflammatory as-
sociation between OPN and CRP is in agreement with pre-
vious findings (36, 37). Taken together, these associations
may contribute, at least in part, to the obesity-associated
inflammatory state, which takes place in the obesity-associ-
ated cardiovascular derangements. OPN also plays a role in
atherosclerosis as a component of the extracellular matrix, a
circulating adhesion molecule, and a chemoattractant cyto-
kine. OPN transgenic mice developed larger atherosclerotic
lesions with an atherogenic diet than nontransgenic mice
(10), whereas OPN-deficient mice developed smaller athero-
sclerotic lesions than normal mice (38). Our data indicate that
vWF concentrations are positively associated with circulat-
ing OPN levels. It is noteworthy that vWF levels have been
suggested as an indirect indicator of thrombosis and ath-
erosclerosis (39). In this sense, our data suggest that the
increased concentrations of OPN found in obesity may con-
tribute to the increased atherosclerosis risk as well as to the
endothelial dysfunction.
The increased levels of OPN found in obesity may be
related to hyperglycemia and to the degree of insulin resis-
tance. OPN concentrations were positively associated with
insulin and negatively with QUICKI even after adjusting for
body fat. High glucose levels have been shown to stimulate
OPN expression through protein kinase C-dependent path-
ways as well as via the hexosamine pathway in cultured rat
aortic smooth muscle cells (40). Moreover, OPN expression
is repressed by insulin-sensitizing peroxisome proliferator-
activated receptor- agonists (41). In this regard, expression
of OPN in omental adipose tissue of obese women with
T2DM was found to be increased in our study compared with
obese NG women.
It has been shown that OPN modulates the expression
and/or activity of proteins that regulate extracellular matrix
remodeling. For example, OPN induces matrix metallopro-
teinase-2 (MMP-2) and MMP-9 activation (8, 19). Expansion
of adipose tissue is a dynamic process in which matrix re-
modeling plays an important role (42, 43). Obesity is asso-
ciated with increased expression of MMP-2 (43) and MMP-9
(44). Taken together, these observations suggest that OPN
might be involved in the remodeling of the adipose tissue
extracellular matrix that takes place in obesity. Plasma levels
and expression in adipose tissue of another protein with
functions related to OPN, SPARC/osteonectin, is similarly
up-regulated in obesity (45, 46), and its adipose expression
reportedly decreases after weight loss in obese patients (47).
Furthermore, osteonectin-null mice exhibit increased adi-
posity without significant differences in overall body weight
(48). In this sense, the analysis of adipose tissue metabolism
in OPN-deficient mice, which also showed a normal body
weight (49), deserves special attention.
OPN levels were strongly associated with hepatic en-
zymes (ALT, AST, and -GT), which are commonly increased
in obese patients in relation to fatty liver. In this sense, OPN
concentrations have been shown to be increased in patients
with fulminant hepatic failure (50) as well as being involved
in the development of nonalcoholic steatohepatitis in mice
(20). The presence of fatty liver in the obese patients included
in our study could underlie the obesity-associated increased
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FIG. 5. Comparison of plasma concentrations of OPN determined in
obese patients before and after weight loss after a dietetic interven-
tion. Values are means SD. Statistical differences were assessed by
two-tailed paired Student’s t test.
TABLE 5. Effect of weight loss in obese male patients after a dietetic intervention
Before weight loss After weight loss P
n 12 12
Age (yr) 33.5  15.1 33.8  15.2
Body weight (kg) 115  20 106  17 0.002
BMI (kg/m2) 36.3  5.1 33.6  4.1 0.002
Body fat (%) 39.5  8.9 36.2  8.9 0.001
Waist circumference (cm) 115  15 103  14 0.0001
WHR 0.97  0.07 0.92  0.07 0.0001
SBP (mm Hg) 140  12 126  13 0.001
DBP (mm Hg) 94  9 86  10 0.004
Glucose (mmol/liter) 5.1  0.6 5.2  0.6 0.340
Insulin (U/ml) 16.7  7.8 14.7  7.0 0.407
QUICKI 0.321  0.026 0.324  0.022 0.706
Leptin (ng/ml) 19.2  7.8 13.0  6.3 0.001
Data are presented as mean  SD. P values compare after vs. before weight loss by two-tailed paired Student’s t tests. To convert glucose
to mg/dl, divide by 0.05551. DBP, Diastolic blood pressure; SBP, systolic blood pressure; WHR, waist-to-hip ratio.
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OPN concentrations observed. However, after adjusting for
ALT, a marker of fatty liver (51), OPN levels were still as-
sociated with body fat percentage. Furthermore, alkaline
phosphatase was also positively associated with OPN con-
centrations. OPN is recognized by osteoblast cells and in-
duces alkaline phosphatase activity, both proteins being ex-
pressed during osteoblastic differentiation. Reciprocally,
OPN can be regulated by alkaline phosphatase (52).
Moderate weight loss has been shown to improve obesity-
associated cardiovascular problems (53). Although the
weight loss experienced by volunteers in our study was only
modest, it was followed by a reduction in OPN concentra-
tions, therefore indicating that plasma OPN appears to be
very responsive to changes in energy balance. OPN is an
established biomarker of cardiovascular events, being up-
regulated in tissues during several pathological processes
including atherosclerosis, valve stenosis, and myocardial in-
farction (54–57). Consequently, the increased levels observed
in obesity herein may be associated with obesity-related car-
diovascular derangements (17, 58). The reduction of OPN
plasma concentrations observed in obese patients after
weight loss may contribute to the improved cardiovascular
risk profile. Therefore, a fall in OPN levels may participate
in the decrease observed in cardiovascular morbidity after
weight loss.
In conclusion, these results indicate that plasma OPN con-
centrations are increased in obese patients. In addition,
mRNA expression of OPN in omental adipose tissue is up-
regulated in obese volunteers being further increased in obe-
sity-associated T2DM. Moreover, weight loss reduces OPN
concentrations, which may contribute to the beneficial effects
accompanying weight reduction. Additional longitudinal
studies should allow us to determine the predictive value of
this biomarker for obesity-associated cardiovascular diseases
as well as for other comorbidities such as T2DM and non-
alcoholic fatty liver disease.
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